← Leaderboards
Paul Stokes Hoffman
University Of Virginia
$6,161,174
Attributed
$6,161,174
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2007–14$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$6,161,174 · 4
By mechanism
R01$3,356,301 · 2
U01$2,575,773 · 1
R21$229,100 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Virginia
Same institution · by research overlap
- Melissa Kendall$4,921,975
- Christopher Charles Moore$2,587,971
- Scott K Heysell$9,245,019
- Kenneth C Bilchick$3,086,054
- Stefan Neubauer$7,234,062
Others in their field
Top investigators on “Infection”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,939,185
- Lawrence Corey · Fred Hutchinson Cancer Center$789,608,171
- Judith S. Currier · University Of California Los Angeles$511,038,212
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$463,711,983
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$415,229,497
Research focus
InfectionBaseLeadPathogenProgramsResearch PersonnelBacteriaParasitesIn VitroMouse ModelDesignMutantAnimal ModelMutationMicrobialPathogenesisElectron MicroscopyBiologicalGene ExpressionPeriplasmInsightCampylobacter JejuniBiochemicalGenes
Grant awards (16)
PFOR inhibitor amixicile for treatment of drug resistant parasites and bacteria$229,100
R21 · FY2014 · AI · contact PI
Nitrothiazolides:Broad-Spectrum Category B Anti-parasitic/bacterial Therapeutics$534,930
U01 · FY2011 · AI · contact PI
Legionella pneumophila developmental cycle & virulence$362,713
R01 · FY2011 · AI · contact PI
Helicobacter pylori: Tactic Responses and Persistence in the Gastric Mucosa$298,307
R01 · FY2011 · DK · contact PI
Nitrothiazolides:Broad-Spectrum Category B Anti-parasitic/bacterial Therapeutics$530,541
U01 · FY2010 · AI · contact PI
Legionella pneumophila developmental cycle & virulence$366,377
R01 · FY2010 · AI · contact PI
Helicobacter pylori: Tactic Responses and Persistence in the Gastric Mucosa$301,320
R01 · FY2010 · DK · contact PI
Nitrothiazolides:Broad-Spectrum Category B Anti-parasitic/bacterial Therapeutics$515,492
U01 · FY2009 · AI · contact PI
Legionella pneumophila developmental cycle & virulence$370,120
R01 · FY2009 · AI · contact PI
Helicobacter pylori: Tactic Responses and Persistence in the Gastric Mucosa$304,364
R01 · FY2009 · DK · contact PI
Nitrothiazolides:Broad-Spectrum Category B Anti-parasitic/bacterial Therapeutics$500,977
U01 · FY2008 · AI · contact PI
Legionella pneumophila developmental cycle & virulence$370,162
R01 · FY2008 · AI · contact PI
Helicobacter pylori: Tactic Responses and Persistence in the Gastric Mucosa$304,364
R01 · FY2008 · DK · contact PI
Nitrothiazolides:Broad-Spectrum Category B Anti-parasitic/bacterial Therapeutics$493,833
U01 · FY2007 · AI · contact PI
Legionella pneumophila developmental cycle & virulence$372,222
R01 · FY2007 · AI · contact PI
Helicobacter pylori: Tactic Responses and Persistence in the Gastric Mucosa$306,352
R01 · FY2007 · DK · contact PI